english.prescrire.org

Subscribe to Prescrire International
  
 Follow us
TwitterFacebook
 

In Prescrire's Spotlight

DSM: still riddled with conflicts of interests

1 October 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Finerenone (Kerendia°) in chronic kidney disease with albuminuria associated with type 2 diabetes

1 October 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Solifenacin + tamsulosin (Vecalmys°/Vesomni°) in benign prostatic hyperplasia: not acceptable

1 October 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Short-term interruption of treatment with a xaban or dabigatran: sometimes fatal thrombosis

1 October 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Environmental impact of drugs: taking drug utilisation data into account

1 October 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
European "pharmaceutical package": letter on clinical data exclusivity

1 October 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Enjoy these features, and more, in our upcoming issues

1 October 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic

1 November 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
New! "Top Texts of 2023", from the editors of Prescrire International

1 August 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Subscribe today for full access to top-quality content from Prescrire International

1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Follow Prescrire International on Facebook and Twitter

1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Receive the free, monthly "Independent Drug & Healthcare Newsletter"

1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Drugs to avoid, in the name of better patient care

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Read more All the subjects in Prescrire's Spotlight >